{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:46:10Z","timestamp":1779331570841,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T00:00:00Z","timestamp":1462579200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T00:00:00Z","timestamp":1462579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Chinese National Science Foundation","doi-asserted-by":"crossref","award":["31170871"],"award-info":[{"award-number":["31170871"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science and Technology Major Project","award":["2012ZX10001-008"],"award-info":[{"award-number":["2012ZX10001-008"]}]},{"name":"National Science and Technology Major Project","award":["2014ZX10001-001"],"award-info":[{"award-number":["2014ZX10001-001"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["A1108467"],"award-info":[{"award-number":["A1108467"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Baylor-UTHouston CFAR","award":["P30AI036211"],"award-info":[{"award-number":["P30AI036211"]}]},{"name":"Chinese National Science Foundation and NIH","award":["81361120406 and AI106574"],"award-info":[{"award-number":["81361120406 and AI106574"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11481-016-9681-x","type":"journal-article","created":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T14:10:25Z","timestamp":1462630225000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor"],"prefix":"10.1007","volume":"11","author":[{"given":"Lihong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"Kimata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,7]]},"reference":[{"key":"9681_CR1","doi-asserted-by":"publisher","first-page":"14238","DOI":"10.1074\/jbc.M201453200","volume":"277","author":"CA Bewley","year":"2002","unstructured":"Bewley CA, Louis JM, Ghirlando R, Clore GM (2002) Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 277:14238\u201314245","journal-title":"J Biol Chem"},{"key":"9681_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.virol.2008.12.031","volume":"386","author":"GC Carter","year":"2009","unstructured":"Carter GC, Bernstone L, Sangani D, Bee JW, Harder T, James W (2009) HIV entry in macrophages is dependent on intact lipid rafts. Virology 386:192\u2013202","journal-title":"Virology"},{"key":"9681_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","volume":"89","author":"DC Chan","year":"1997","unstructured":"Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263\u2013273","journal-title":"Cell"},{"key":"9681_CR4","doi-asserted-by":"publisher","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","volume":"95","author":"DC Chan","year":"1998","unstructured":"Chan DC, Chutkowski CT, Kim PS (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 95:15613\u201315617","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9681_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1128\/MMBR.67.2.226-237.2003","volume":"67","author":"N Chazal","year":"2003","unstructured":"Chazal N, Gerlier D (2003) Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev 67:226\u2013237, table of contents","journal-title":"Microbiol Mol Biol Rev"},{"key":"9681_CR6","doi-asserted-by":"publisher","first-page":"34558","DOI":"10.1074\/jbc.M112.390393","volume":"287","author":"H Chong","year":"2012","unstructured":"Chong H, Yao X, Sun J, Qiu Z, Zhang M, Waltersperger S, Wang M, Cui S, He Y (2012) The M-T hook structure is critical for design of HIV-1 fusion inhibitors. J Biol Chem 287:34558\u201334568","journal-title":"J Biol Chem"},{"key":"9681_CR7","doi-asserted-by":"publisher","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","volume":"74","author":"CA Derdeyn","year":"2000","unstructured":"Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O\u2019Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74:8358\u20138367","journal-title":"J Virol"},{"key":"9681_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2013-08-521229","volume":"123","author":"CA Didigu","year":"2014","unstructured":"Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW (2014) Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood 123:61\u201369","journal-title":"Blood"},{"key":"9681_CR9","doi-asserted-by":"publisher","first-page":"36ra43","DOI":"10.1126\/scitranslmed.3000931","volume":"2","author":"DL DiGiusto","year":"2010","unstructured":"DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2:36ra43","journal-title":"Sci Transl Med"},{"key":"9681_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12974-015-0447-9","volume":"12","author":"DM Durrant","year":"2015","unstructured":"Durrant DM, Daniels BP, Pasieka T, Dorsey D, Klein RS (2015) CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system. J Neuroinflammation 12:233","journal-title":"J Neuroinflammation"},{"key":"9681_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","volume":"70","author":"DM Eckert","year":"2001","unstructured":"Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70:777\u2013810","journal-title":"Annu Rev Biochem"},{"key":"9681_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1128\/JVI.78.2.568-575.2004","volume":"78","author":"M Egelhofer","year":"2004","unstructured":"Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, von Laer D (2004) Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 78:568\u2013575","journal-title":"J Virol"},{"key":"9681_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/76095","volume":"25","author":"A Follenzi","year":"2000","unstructured":"Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217\u2013222","journal-title":"Nat Genet"},{"key":"9681_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20051970","volume":"203","author":"WG Glass","year":"2006","unstructured":"Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203:35\u201340","journal-title":"J Exp Med"},{"key":"9681_CR15","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1128\/JVI.69.11.6705-6711.1995","volume":"69","author":"J He","year":"1995","unstructured":"He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69:6705\u20136711","journal-title":"J Virol"},{"key":"9681_CR16","doi-asserted-by":"publisher","first-page":"16332","DOI":"10.1073\/pnas.0807335105","volume":"105","author":"Y He","year":"2008","unstructured":"He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q (2008) Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A 105:16332\u201316337","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9681_CR17","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1128\/JVI.06665-11","volume":"86","author":"H Hu","year":"2012","unstructured":"Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin SJ, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P (2012) A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 86:2978\u20132989","journal-title":"J Virol"},{"key":"9681_CR18","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1073\/pnas.0901007106","volume":"106","author":"P Ingallinella","year":"2009","unstructured":"Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD, Pessi A (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 106:5801\u20135806","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9681_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/8414","volume":"5","author":"JT Kimata","year":"1999","unstructured":"Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J (1999) Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 5:535\u2013541","journal-title":"Nat Med"},{"key":"9681_CR20","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari JP, Henry K, O\u2019Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175\u20132185","journal-title":"N Engl J Med"},{"key":"9681_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1089\/088922201300343690","volume":"17","author":"Z Liao","year":"2001","unstructured":"Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE (2001) Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 17:1009\u20131019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"9681_CR22","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.1074\/jbc.M411141200","volume":"280","author":"S Liu","year":"2005","unstructured":"Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280:11259\u201311273","journal-title":"J Biol Chem"},{"key":"9681_CR23","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1128\/JVI.00520-11","volume":"85","author":"L Liu","year":"2011","unstructured":"Liu L, Wen M, Wang W, Wang S, Yang L, Liu Y, Qian M, Zhang L, Shao Y, Kimata JT, Zhou P (2011) Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J Virol 85:8467\u20138476","journal-title":"J Virol"},{"key":"9681_CR24","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1128\/JVI.01038-12","volume":"87","author":"L Liu","year":"2013","unstructured":"Liu L, Wang W, Yang L, Ren H, Kimata JT, Zhou P (2013) Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol 87:1899\u20131905","journal-title":"J Virol"},{"key":"9681_CR25","doi-asserted-by":"publisher","first-page":"9134","DOI":"10.1073\/pnas.95.16.9134","volume":"95","author":"VN Malashkevich","year":"1998","unstructured":"Malashkevich VN, Chan DC, Chutkowski CT, Kim PS (1998) Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A 95:9134\u20139139","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9681_CR26","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1084\/jem.160.5.1558","volume":"160","author":"ME Medof","year":"1984","unstructured":"Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558\u20131578","journal-title":"J Exp Med"},{"key":"9681_CR27","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1128\/JVI.80.7.3249-3258.2006","volume":"80","author":"GB Melikyan","year":"2006","unstructured":"Melikyan GB, Egelhofer M, von Laer D (2006) Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol 80:3249\u20133258","journal-title":"J Virol"},{"key":"9681_CR28","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1128\/JVI.70.8.5564-5571.1996","volume":"70","author":"AD Miller","year":"1996","unstructured":"Miller AD, Chen F (1996) Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J Virol 70:5564\u20135571","journal-title":"J Virol"},{"key":"9681_CR29","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","volume":"72","author":"EJ Platt","year":"1998","unstructured":"Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72:2855\u20132864","journal-title":"J Virol"},{"key":"9681_CR30","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1128\/JVI.00709-09","volume":"83","author":"EJ Platt","year":"2009","unstructured":"Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC (2009) Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83:8289\u20138292","journal-title":"J Virol"},{"key":"9681_CR31","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1128\/JVI.76.10.4709-4722.2002","volume":"76","author":"W Popik","year":"2002","unstructured":"Popik W, Alce TM, Au WC (2002) Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 76:4709\u20134722","journal-title":"J Virol"},{"key":"9681_CR32","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1128\/JVI.02108-09","volume":"84","author":"MS Seaman","year":"2010","unstructured":"Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439\u20131452","journal-title":"J Virol"},{"key":"9681_CR33","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1128\/AAC.05015-11","volume":"56","author":"CA Stoddart","year":"2012","unstructured":"Stoddart CA, Nault G, Galkina SA, Bousquet-Gagnon N, Bridon D, Quraishi O (2012) Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy\/Liv mice. Antimicrob Agents Chemother 56:2162\u20132165","journal-title":"Antimicrob Agents Chemother"},{"key":"9681_CR34","doi-asserted-by":"publisher","first-page":"12585","DOI":"10.1128\/JVI.01726-08","volume":"82","author":"Y Takeuchi","year":"2008","unstructured":"Takeuchi Y, McClure MO, Pizzato M (2008) Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82:12585\u201312588","journal-title":"J Virol"},{"key":"9681_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370:901\u2013910","journal-title":"N Engl J Med"},{"key":"9681_CR36","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1016\/j.vaccine.2009.08.056","volume":"27","author":"C Tsai","year":"2009","unstructured":"Tsai C, Caillet C, Hu H, Zhou F, Ding H, Zhang G, Zhou B, Wang S, Lu S, Buchy P, Deubel V, Vogel FR, Zhou P (2009) Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27:6777\u20136790","journal-title":"Vaccine"},{"key":"9681_CR37","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/mt.sj.6300124","volume":"15","author":"J van Lunzen","year":"2007","unstructured":"van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, Schilz A, Kuehlcke K, Naundorf S, Martinius H, Hermann F, Giroglou T, Newrzela S, Muller I, Brauer F, Brandenburg G, Alexandrov A, von Laer D (2007) Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 15:1024\u20131033","journal-title":"Mol Ther"},{"key":"9681_CR38","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","volume":"46","author":"X Wei","year":"2002","unstructured":"Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896\u20131905","journal-title":"Antimicrob Agents Chemother"},{"key":"9681_CR39","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/387426a0","volume":"387","author":"W Weissenhorn","year":"1997","unstructured":"Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426\u2013430","journal-title":"Nature"},{"key":"9681_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1742-4690-7-79","volume":"7","author":"M Wen","year":"2010","unstructured":"Wen M, Arora R, Wang H, Liu L, Kimata JT, Zhou P (2010) GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology 7:79","journal-title":"Retrovirology"},{"key":"9681_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000509","volume":"5","author":"Y Wexler-Cohen","year":"2009","unstructured":"Wexler-Cohen Y, Shai Y (2009) Membrane-anchored HIV-1N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog 5, e1000509","journal-title":"PLoS Pathog"},{"key":"9681_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1182\/blood-2013-01-482224","volume":"122","author":"PM Younan","year":"2013","unstructured":"Younan PM, Polacino P, Kowalski JP, Peterson CW, Maurice NJ, Williams NP, Ho O, Trobridge GD, Von Laer D, Prlic M, Beard BC, DeRosa S, Hu SL, Kiem HP (2013) Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 122:179\u2013187","journal-title":"Blood"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-016-9681-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11481-016-9681-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-016-9681-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-016-9681-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:12:19Z","timestamp":1589731939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11481-016-9681-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,7]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["9681"],"URL":"https:\/\/doi.org\/10.1007\/s11481-016-9681-x","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"value":"1557-1890","type":"print"},{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,7]]},"assertion":[{"value":"22 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}